Zymeworks
Manufacturing · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
114 E 4th Ave Ste 800, Vancouver, Britis...Phone Number
(604) 678-1388Website
www.zymeworks.comRevenue
$81.3 MillionStock Symbol
ZYMEIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Zymeworks
Zymeworks Inc. is a global biotechnology company focused on developing, managing, and commercializing innovative biotherapeutics for the treatment of cancer, autoimmune disorders, and other serious diseases with significant unmet medical needs. The company combines proprietary antibody engineering technologies with a strategic healthcare asset management approach to create long-term value through the discovery of novel therapeutics and the optimization of licensed healthcare assets.Explore more
Zymeworks Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zymeworks your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Zymeworks has new funding data
Zymeworks, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Zymeworks is spiking on competitors!
Product Launch: Get notified when Zymeworks launches new products
Website visits: Recent activity has been detected on your website
Click to see if Zymeworks had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Zymeworks
Check if Zymeworks has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Zymeworks recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Zymeworks as Masked Content
Find 3 more new buyers
Compare Similar Companies to Zymeworks
Compare insights from companies similar to Zymeworks, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zymeworks is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zymeworks is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zymeworks.
Zymeworks financials insights
Gather financial insights about Zymeworks, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$22.3M
2015
Multiple Rounds
$34.4M
2016
Series A
$61.5M
2017
Stock Offering
$63.6M
2018
Stock Offering
$97.8M
2019
Stock Offering
$201.3M
2020
Stock Offering
$320.8M
Zymeworks Tech Stack
A closer look at the technologies used by Zymeworks
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Person-Based
Earnings, Acquisitions, Finance
Person-Based
Earnings, Acquisitions, Finance
Person-Based
Medical Research, Pharmaceuticals
Zymeworks News & Media
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
VANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2026 and provided a summary of recent business highlights. In light of the previously announced proposed acquisition of Theravance Biopharma, the Company has elected not to host aZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
Issued on behalf of GT Biopharma, Inc. GT Biopharma, Inc. (NASDAQ: GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development...Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Zymeworks Inc. (NASDAQ:ZYME) is one of the best biotech stocks on this list. TheFly reported on June 9 that Truist Securities initiated coverage of ZYME with a Buy rating and a $28 price target, down from $40. The firm highlighted ZYME […]
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zymeworks
Sign Up For FreeTo access detailed company insights
Zymeworks Inc. is a global biotechnology company focused on developing, managing, and commercializing innovative biotherapeutics for the treatment of cancer, autoimmune disorders, and other serious diseases with significant unmet medical needs. The company combines proprietary antibody engineering technologies with a strategic healthcare asset mana... Read More
